156 related articles for article (PubMed ID: 22307932)
41. CD26/dipeptidyl peptidase IV and its role in cancer.
Pro B; Dang NH
Histol Histopathol; 2004 Oct; 19(4):1345-51. PubMed ID: 15375776
[TBL] [Abstract][Full Text] [Related]
42. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.
Zhao RY; Erickson HK; Leece BA; Reid EE; Goldmacher VS; Lambert JM; Chari RV
J Med Chem; 2012 Jan; 55(2):766-82. PubMed ID: 22148292
[TBL] [Abstract][Full Text] [Related]
44. Regulation and roles of CD26/DPPIV in hematopoiesis and diseases.
Aliyari Serej Z; Ebrahimi Kalan A; Mehdipour A; Nozad Charoudeh H
Biomed Pharmacother; 2017 Jul; 91():88-94. PubMed ID: 28448874
[TBL] [Abstract][Full Text] [Related]
45. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.
Matheeussen V; Baerts L; De Meyer G; De Keulenaer G; Van der Veken P; Augustyns K; Dubois V; Scharpé S; De Meester I
Biol Chem; 2011 Mar; 392(3):189-98. PubMed ID: 21194356
[TBL] [Abstract][Full Text] [Related]
46. Model prodrugs designed for the intestinal peptide transporter. A synthetic approach for coupling of hydroxy-containing compounds to dipeptides.
Friedrichsen GM; Nielsen CU; Steffansen B; Begtrup M
Eur J Pharm Sci; 2001 Aug; 14(1):13-9. PubMed ID: 11457645
[TBL] [Abstract][Full Text] [Related]
47. Water-soluble prodrugs of cyclosporine A with tailored conversion rates.
Hamel AR; Hubler F; Mutter M
J Pept Res; 2005 Mar; 65(3):364-74. PubMed ID: 15787967
[TBL] [Abstract][Full Text] [Related]
48. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
49. Crystal structure of CD26/dipeptidyl-peptidase IV in complex with adenosine deaminase reveals a highly amphiphilic interface.
Weihofen WA; Liu J; Reutter W; Saenger W; Fan H
J Biol Chem; 2004 Oct; 279(41):43330-5. PubMed ID: 15213224
[TBL] [Abstract][Full Text] [Related]
50. Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery?
Scharpé S; De Meester I
Verh K Acad Geneeskd Belg; 2001; 63(1):5-32; discussion 32-3. PubMed ID: 11284388
[TBL] [Abstract][Full Text] [Related]
51. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs.
Krise JP; Narisawa S; Stella VJ
J Pharm Sci; 1999 Sep; 88(9):922-7. PubMed ID: 10479355
[TBL] [Abstract][Full Text] [Related]
52. A new aliphatic amino prodrug system for the delivery of small molecules and proteins utilizing novel PEG derivatives.
Greenwald RB; Zhao H; Yang K; Reddy P; Martinez A
J Med Chem; 2004 Jan; 47(3):726-34. PubMed ID: 14736253
[TBL] [Abstract][Full Text] [Related]
53. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds.
Greenwald RB; Pendri A; Conover CD; Zhao H; Choe YH; Martinez A; Shum K; Guan S
J Med Chem; 1999 Sep; 42(18):3657-67. PubMed ID: 10479297
[TBL] [Abstract][Full Text] [Related]
54. Expression of CD26 and its association with dipeptidyl peptidase IV activity in lymphocytes of type 2 diabetes patients.
Bellé LP; Bitencourt PE; de Bona KS; Zanette RA; Moresco RN; Moretto MB
Cell Biochem Biophys; 2011 Nov; 61(2):297-302. PubMed ID: 21614532
[TBL] [Abstract][Full Text] [Related]
55. Aminocarbonyloxymethyl ester prodrugs of flufenamic acid and diclofenac: suppressing the rearrangement pathway in aqueous media.
Ribeiro L; Silva N; Iley J; Rautio J; Järvinen T; Mota-Filipe H; Moreira R; Mendes E
Arch Pharm (Weinheim); 2007 Jan; 340(1):32-40. PubMed ID: 17206608
[TBL] [Abstract][Full Text] [Related]
56. Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation.
Erez R; Ebner S; Attali B; Shabat D
Bioorg Med Chem Lett; 2008 Jan; 18(2):816-20. PubMed ID: 18061452
[TBL] [Abstract][Full Text] [Related]
57. Synthesis, characterization, and biological evaluation of novel diclofenac prodrugs.
Bandgar BP; Sarangdhar RJ; Ahamed FA; Viswakarma S
J Med Chem; 2011 Mar; 54(5):1202-10. PubMed ID: 21250699
[TBL] [Abstract][Full Text] [Related]
58. Primaquine dipeptide derivatives bearing an imidazolidin-4-one moiety at the N-terminus as potential antimalarial prodrugs.
Vale N; Nogueira F; do Rosário VE; Gomes P; Moreira R
Eur J Med Chem; 2009 Jun; 44(6):2506-16. PubMed ID: 19232784
[TBL] [Abstract][Full Text] [Related]
59. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation.
Aertgeerts K; Ye S; Tennant MG; Kraus ML; Rogers J; Sang BC; Skene RJ; Webb DR; Prasad GS
Protein Sci; 2004 Feb; 13(2):412-21. PubMed ID: 14718659
[TBL] [Abstract][Full Text] [Related]
60. Systematic analysis of a dipeptide library for inhibitor development using human dipeptidyl peptidase IV produced by a Saccharomyces cerevisiae expression system.
Hikida A; Ito K; Motoyama T; Kato R; Kawarasaki Y
Biochem Biophys Res Commun; 2013 Jan; 430(4):1217-22. PubMed ID: 23268343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
